Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Grows By 118.4%

by · The Markets Daily

Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 1,228,229 shares, an increase of 118.4% from the May 14th total of 562,363 shares. Currently, 2.7% of the company’s stock are short sold. Based on an average daily volume of 44,575,019 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Report on Liminatus Pharma

Liminatus Pharma Stock Performance

Shares of NASDAQ LIMN opened at $0.12 on Monday. The stock has a fifty day simple moving average of $0.18 and a two-hundred day simple moving average of $0.46. Liminatus Pharma has a 1-year low of $0.12 and a 1-year high of $33.66. The firm has a market cap of $5.48 million and a price-to-earnings ratio of -0.28.

Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.03) earnings per share for the quarter.

About Liminatus Pharma

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Featured Stories